12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Anaphore, arGEN-X B.V. deal

Anaphore changed its name to RuiYi Inc. and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X. RuiYi said the moves are part of the company's shift in strategy to discover and develop biologics in China, including mAbs that target GPCRs. The shift follows Anaphore's...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >